NCT04524663View on ClinicalTrials.gov

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 19, 2020

Primary Completion Date

May 15, 2021

Study Completion Date

May 15, 2021

Conditions
Covid19
Interventions
DRUG

Camostat Mesilate

Camostat Mesilate administered as oral tablets

DRUG

Placebo

Placebo to match camostat mesilate

OTHER

Standard of Care Treatment

Standard of Care Treatment for COVID-19 Infection

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04524663 - Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients | Biotech Hunter | Biotech Hunter